KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Accounts Payables (2016 - 2025)

Eli Lilly's Accounts Payables history spans 17 years, with the latest figure at $5.4 billion for Q4 2025.

  • For Q4 2025, Accounts Payables rose 66.58% year-over-year to $5.4 billion; the TTM value through Dec 2025 reached $5.4 billion, up 66.58%, while the annual FY2025 figure was $5.4 billion, 66.58% up from the prior year.
  • Accounts Payables reached $5.4 billion in Q4 2025 per LLY's latest filing, up from $4.3 billion in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $5.4 billion in Q4 2025 to a low of $1.4 billion in Q1 2022.
  • Average Accounts Payables over 5 years is $2.6 billion, with a median of $2.5 billion recorded in 2023.
  • Peak YoY movement for Accounts Payables: dropped 12.58% in 2022, then surged 66.58% in 2025.
  • A 5-year view of Accounts Payables shows it stood at $1.7 billion in 2021, then rose by 15.56% to $1.9 billion in 2022, then soared by 34.61% to $2.6 billion in 2023, then rose by 24.25% to $3.2 billion in 2024, then skyrocketed by 66.58% to $5.4 billion in 2025.
  • Per Business Quant, the three most recent readings for LLY's Accounts Payables are $5.4 billion (Q4 2025), $4.3 billion (Q3 2025), and $4.1 billion (Q2 2025).